Shopping Cart 0
Cart Subtotal
USD 0

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc (JAZZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16

Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17

Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For USD 125 Million 19

Venture Financing 20

Arrivo BioVentures Raises USD49 Million in Venture Financing 20

Alize Pharma Raises USD1.9 Million in Venture Financing 21

Alize Pharma Raises USD6.4 Million in Series A Financing 22

Celator Pharma Raises USD 39 Million In Venture Financing 23

Celator Pharma Raises USD4.1 Million in Venture Financing 24

Alize Pharma Raises USD 4 Million In Venture Financing 25

Partnerships 26

Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27

The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28

Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30

Merger 31

Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31

Licensing Agreements 33

Jazz Pharma Enters into License Agreement with XL-protein 33

Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34

Jazz Pharma Amends Licensing Agreement with Pfenex 35

Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37

Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38

EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40

Equity Offering 41

Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41

Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43

Debt Offering 45

Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45

Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46

Asset Transactions 47

TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47

Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48

Aytu BioScience Acquires ProstaScint from Jazz Pharma 49

Essex Bidco Acquires Assets from Jazz Pharma 50

Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 53

Acquisition 55

Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55

Jazz Pharma Acquires Alize Pharma 57

AstraZeneca May Acquire Ariad Pharma 58

Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For USD 993.4 Million 60

Jazz Pharma Acquires Eusa Pharma For Up To USD 730 Million 62

Jazz Pharmaceuticals Plc-Key Competitors 65

Jazz Pharmaceuticals Plc-Key Employees 66

Jazz Pharmaceuticals Plc-Locations And Subsidiaries 67

Head Office 67

Other Locations & Subsidiaries 67

Recent Developments 69

Financial Announcements 69

Nov 06, 2018: Jazz Pharmaceuticals announces third quarter 2018 financial results 69

Aug 07, 2018: Jazz Pharmaceuticals announces second quarter 2018 financial results 71

May 08, 2018: Jazz Pharmaceuticals Reports First Quarter 2018 Financial Results 73

Feb 27, 2018: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results 75

Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 77

Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 78

May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 79

Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 81

Corporate Communications 83

Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 83

Product News 84

08/03/2017: Jazz Pharmaceuticals Announces FDA Approval of Vyxeos Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) 84

08/03/2017: Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update 85

03/19/2018: Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos (CPX-351) outside the United States 86

02/08/2018: National Comprehensive Cancer Network adds Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology 87

Product Approvals 88

Nov 03, 2017: Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia 88

May 31, 2017: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status 89

Apr 03, 2017: Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia 90

Clinical Trials 91

Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Vyxeos at ASH 2017 Annual Meeting 91

Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 94

Appendix 95

Methodology 95

About GlobalData 95

Contact Us 95

Disclaimer 95


List Of Figure

List of Figures

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16

Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17

Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For USD 125 Million 19

Arrivo BioVentures Raises USD49 Million in Venture Financing 20

Alize Pharma Raises USD1.9 Million in Venture Financing 21

Alize Pharma Raises USD6.4 Million in Series A Financing 22

Celator Pharma Raises USD 39 Million In Venture Financing 23

Celator Pharma Raises USD4.1 Million in Venture Financing 24

Alize Pharma Raises USD 4 Million In Venture Financing 25

Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27

The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28

Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30

Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31

Jazz Pharma Enters into License Agreement with XL-protein 33

Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34

Jazz Pharma Amends Licensing Agreement with Pfenex 35

Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37

Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38

EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40

Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41

Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43

Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45

Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46

TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47

Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48

Aytu BioScience Acquires ProstaScint from Jazz Pharma 49

Essex Bidco Acquires Assets from Jazz Pharma 50

Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 53

Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55

Jazz Pharma Acquires Alize Pharma 57

AstraZeneca May Acquire Ariad Pharma 58

Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For USD 993.4 Million 60

Jazz Pharma Acquires Eusa Pharma For Up To USD 730 Million 62

Jazz Pharmaceuticals Plc, Key Competitors 65

Jazz Pharmaceuticals Plc, Key Employees 66

Jazz Pharmaceuticals Plc, Other Locations 67

Jazz Pharmaceuticals Plc, Subsidiaries 67

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Jazz Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc (JAZZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16

Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17

Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For USD 125 Million 19

Venture Financing 20

Arrivo BioVentures Raises USD49 Million in Venture Financing 20

Alize Pharma Raises USD1.9 Million in Venture Financing 21

Alize Pharma Raises USD6.4 Million in Series A Financing 22

Celator Pharma Raises USD 39 Million In Venture Financing 23

Celator Pharma Raises USD4.1 Million in Venture Financing 24

Alize Pharma Raises USD 4 Million In Venture Financing 25

Partnerships 26

Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27

The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28

Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30

Merger 31

Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31

Licensing Agreements 33

Jazz Pharma Enters into License Agreement with XL-protein 33

Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34

Jazz Pharma Amends Licensing Agreement with Pfenex 35

Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37

Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38

EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40

Equity Offering 41

Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41

Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43

Debt Offering 45

Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45

Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46

Asset Transactions 47

TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47

Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48

Aytu BioScience Acquires ProstaScint from Jazz Pharma 49

Essex Bidco Acquires Assets from Jazz Pharma 50

Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 53

Acquisition 55

Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55

Jazz Pharma Acquires Alize Pharma 57

AstraZeneca May Acquire Ariad Pharma 58

Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For USD 993.4 Million 60

Jazz Pharma Acquires Eusa Pharma For Up To USD 730 Million 62

Jazz Pharmaceuticals Plc-Key Competitors 65

Jazz Pharmaceuticals Plc-Key Employees 66

Jazz Pharmaceuticals Plc-Locations And Subsidiaries 67

Head Office 67

Other Locations & Subsidiaries 67

Recent Developments 69

Financial Announcements 69

Nov 06, 2018: Jazz Pharmaceuticals announces third quarter 2018 financial results 69

Aug 07, 2018: Jazz Pharmaceuticals announces second quarter 2018 financial results 71

May 08, 2018: Jazz Pharmaceuticals Reports First Quarter 2018 Financial Results 73

Feb 27, 2018: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results 75

Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 77

Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 78

May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 79

Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 81

Corporate Communications 83

Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 83

Product News 84

08/03/2017: Jazz Pharmaceuticals Announces FDA Approval of Vyxeos Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) 84

08/03/2017: Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update 85

03/19/2018: Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos (CPX-351) outside the United States 86

02/08/2018: National Comprehensive Cancer Network adds Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology 87

Product Approvals 88

Nov 03, 2017: Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia 88

May 31, 2017: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status 89

Apr 03, 2017: Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia 90

Clinical Trials 91

Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Vyxeos at ASH 2017 Annual Meeting 91

Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 94

Appendix 95

Methodology 95

About GlobalData 95

Contact Us 95

Disclaimer 95


List Of Figure

List of Figures

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16

Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17

Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For USD 125 Million 19

Arrivo BioVentures Raises USD49 Million in Venture Financing 20

Alize Pharma Raises USD1.9 Million in Venture Financing 21

Alize Pharma Raises USD6.4 Million in Series A Financing 22

Celator Pharma Raises USD 39 Million In Venture Financing 23

Celator Pharma Raises USD4.1 Million in Venture Financing 24

Alize Pharma Raises USD 4 Million In Venture Financing 25

Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27

The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28

Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29

Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30

Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31

Jazz Pharma Enters into License Agreement with XL-protein 33

Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34

Jazz Pharma Amends Licensing Agreement with Pfenex 35

Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37

Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38

EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40

Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41

Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43

Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45

Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46

TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47

Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48

Aytu BioScience Acquires ProstaScint from Jazz Pharma 49

Essex Bidco Acquires Assets from Jazz Pharma 50

Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD 95 Million 53

Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55

Jazz Pharma Acquires Alize Pharma 57

AstraZeneca May Acquire Ariad Pharma 58

Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For USD 993.4 Million 60

Jazz Pharma Acquires Eusa Pharma For Up To USD 730 Million 62

Jazz Pharmaceuticals Plc, Key Competitors 65

Jazz Pharmaceuticals Plc, Key Employees 66

Jazz Pharmaceuticals Plc, Other Locations 67

Jazz Pharmaceuticals Plc, Subsidiaries 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Jazz Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.